Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015
This article was originally published in The Pink Sheet Daily
Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.
You may also be interested in...
Translational R&D Models Like Precompetitive Alliances Needed To Energize Drug Discovery - Indian Symposium
AHMEDABAD, India - Precompetitive collaborations between pharmaceutical companies mainly aimed at identifying biomarkers should intensify further to help weed out undesirable molecules in trials sooner than in expensive Phase II or III studies. Industry-academia alliances are increasingly gravitating in the same direction
MUMBAI - A deal that has been brewing for nearly two years has finally taken a concrete shape. Germany's Bayer Healthcare and India's Zydus Cadila have agreed to form an equal stake company that will see Bayer move its existing sales and marketing business in India to the new enterprise
MUMBAI - Large companies with well-oiled manufacturing skills and marketing networks in the growing Indian market have demonstrated their attractiveness as buyout targets for multinational companies, but analysts suggest that there could also be a significant interest developing from both sides of the spectrum in signing up proportionately profitable joint ventures for building strong manufacturing assets